1. Home
  2. HCI vs PHVS Comparison

HCI vs PHVS Comparison

Compare HCI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HCI Group Inc.

HCI

HCI Group Inc.

HOLD

Current Price

$188.14

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$23.90

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCI
PHVS
Founded
2006
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HCI
PHVS
Price
$188.14
$23.90
Analyst Decision
Strong Buy
Buy
Analyst Count
5
9
Target Price
$230.00
$39.44
AVG Volume (30 Days)
164.0K
546.3K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
0.86%
N/A
EPS Growth
32.29
N/A
EPS
15.80
N/A
Revenue
$816,578,000.00
N/A
Revenue This Year
$19.65
N/A
Revenue Next Year
$9.97
N/A
P/E Ratio
$11.76
N/A
Revenue Growth
8.75
N/A
52 Week Low
$106.89
$11.51
52 Week High
$210.50
$29.80

Technical Indicators

Market Signals
Indicator
HCI
PHVS
Relative Strength Index (RSI) 59.75 47.33
Support Level $183.33 $23.61
Resistance Level $190.46 $25.44
Average True Range (ATR) 5.67 1.95
MACD 2.13 -0.31
Stochastic Oscillator 93.68 13.24

Price Performance

Historical Comparison
HCI
PHVS

About HCI HCI Group Inc.

HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: